INTERNATIONAL CONGRESS OF
PharmacoGenetics
The Role of Bioresonance in Modulating Epigenetics and Cancer Signaling: An Innovative Approach Based on Molecular Evidence and Resonance Technologies
-
Sahar Masoomi,1,*
1. Researcher in Medical Genetics, Bioresonance Therapy, Epigenetics, Pharmaceutical and medical Biotechnology, and Psycho-Oncology
- Introduction: In recent years, advances in medical science and emerging technologies have facilitated the rise of non-invasive and targeted therapeutic strategies. Among them, Bioresonance Therapy (BRT) has gained attention as a method based on electromagnetic oscillations of cells and tissues to modulate biological signaling and epigenetic pathways. By recording and processing cellular energy fluctuations, bioresonance aims to restore homeostasis and correct signaling disruptions associated with diseases, particularly cancer. Epigenetic dysregulation and aberrant signaling are central to cancer initiation and progression. Alterations in DNA methylation, histone modification, and microRNA expression can promote uncontrolled cell proliferation, resistance to apoptosis, and metastasis. Bioresonance, through resonance-based modulation, has the potential to influence these disturbances and regulate pathways related to growth, differentiation, and immune responses. Preliminary clinical evidence indicates that BRT, when used as an adjunctive therapy, may reduce side effects of chemotherapy and radiotherapy, enhance immune system activity, and improve patient quality of life. Although precise mechanisms remain under investigation, resonance-based models provide a framework for identifying molecular biomarkers and epigenetic changes associated with therapeutic responses. Overall, molecular and clinical findings suggest bioresonance is a promising strategy for modulating cancer signaling and epigenetics, offering the possibility of more personalized and less toxic interventions.
- Methods: This study systematically reviewed articles published between 2015 and 2025 focusing on bioresonance in relation to epigenetics and cancer signaling. Articles were selected for their relevance to molecular mechanisms, clinical outcomes, and therapeutic potential. Databases searched included PubMed, Scopus, Web of Science, and SpringerLink, with keywords such as “bioresonance therapy,” “epigenetics,” “cancer signaling,” and “oncology treatment.” Extracted data included molecular mechanisms, therapeutic outcomes, and both advantages and limitations of bioresonance in oncology.
- Results: Findings from the reviewed studies show that bioresonance significantly influences epigenetic processes and cancer-related pathways. Evidence indicates that regulated electromagnetic waves can modulate the expression of genes critical for cell cycle control, apoptosis, oxidative stress, and immune regulation, especially tumor suppressor genes and nuclear signaling factors. Mechanistically, bioresonance functions through cellular resonance: devices deliver specific electromagnetic frequencies to establish coordination and energy balance within cells. These frequencies adjust electrical and chemical signals, activating or inhibiting pathways related to cell proliferation and death. In parallel, bioresonance may enhance immune responses and lower cancer cell resistance to conventional therapies. The therapeutic method involves connecting patients to the device through specialized electrodes. Each treatment session typically lasts 30–60 minutes, with frequencies adjusted via software according to clinical needs and cell targets. This approach is non-invasive and has shown minimal adverse effects. Human and preclinical studies report improved immune function, increased cancer cell sensitivity to chemotherapy and radiotherapy, and enhanced patient well-being. Bioresonance also contributes to restoring cellular energy balance and reducing oxidative stress, factors linked to drug resistance. Nonetheless, the lack of standardized protocols and variability in patient response highlight the need for further controlled and long-term research. In summary, bioresonance appears not only as a supportive therapy but also as a potential technology for modulating epigenetic and tumor-related pathways. Its ability to integrate with existing treatments underscores the importance of future studies to refine treatment parameters and establish its clinical value.
- Conclusion: Current evidence demonstrates that bioresonance, as an advanced technology, can selectively modulate cancer-related signaling and guide epigenetic changes toward restoring homeostasis and energy balance. The resonance generated by coordinated frequencies enables synchronization between molecular processes and cellular networks, offering control over tumor growth, improved responsiveness to conventional therapies, and stronger immune support. Due to its non-invasive nature and precise frequency adjustment, bioresonance holds promise as a complementary cancer treatment. It can enhance quality of life, reduce side effects of standard therapies, and promote cellular recovery without damaging healthy tissues. Still, challenges remain, including variability in patient outcomes, need for specialized equipment, lack of standardized global protocols, and limited long-term studies. Taken together, bioresonance offers significant advantages—non-invasiveness, improved quality of life, modulation of cellular and epigenetic pathways, and greater treatment sensitivity—while its limitations point to the necessity of further refinement and rigorous clinical validation. This balance highlights bioresonance as both a promising adjunctive tool and a field requiring deeper exploration before widespread application.
- Keywords: Bioresonance, Epigenetics, Cancer signaling pathways, Non-invasive targeted therapy, Molecular modul
